View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Bibliography 262 Volume Measurements of the Anal Sphincter Complex in Healthy Controls and Fecal-Incontinent Patients With a Three-Dimensional Reconstruction of Endoanal Ultrasonography Images. Dis Colon Rectum. 2005 Mar;48(3):540-8. 56. Veldt BJ, Hansen BE, Eijkemans MJ, Knegt RJ, Stijnen T, Habbema JD, Schalm SW. Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C. Aliment Pharmacol Ther. 2005 Mar 1;21(5):539-47. 57. West RL, Dwarkasing S, Briel JW, Hansen BE, Hussain SM, Schouten WR, Kuipers EJ. Can three-dimensional endoanal ultrasonography detect external anal sphincter atrophy? A comparison with endoanal magnetic resonance imaging. Int J Colorectal Dis. 2005 Jul;20(4):328-33 58. Tapirdamaz O, Pravica V, Metselaar HJ, Hansen B, Moons LM, van Meurs JB, Hutchinson IV, Shaw J, Agarwal K, Adams DH, Day CP, Kwekkeboom J. Polymorphisms in the T-cell regulatory gene CTLA-4 infl uence the rate of acute rejection after liver transplantation. Gut. 2005 Nov 18; [Epub ahead of print] 59. van der Eijk AA, Niesters HG, Hansen BE, Pas SD, Richardus JH, Mostert M, Janssen HL, Schalm SW, de Man RA. Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1173-9. 60. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005 Aug;43(2):250-7. 61. West RL, Van der Woude CJ, Endtz HP, Hansen BE, Ouwedijk M, Boelens HA, Kusters JG, Kuipers EJ. Perianal fi stulas in Crohn’s disease are predominantly colonized by skin fl ora: implications for antibiotic treatment? Dig Dis Sci. 2005 Jul;50(7):1260-3. 62. Tha-In T, Hesselink DA, Tilanus HW, Elshove L, Wilschut AL, Hansen BE, van Gelder T, Metselaar HJ. Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. Clin Transplant. 2005 Aug;19(4):537-42. 63. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat. 2005 Jul;12(4):364-72. 64. Gosselink MP, West RL, Kuipers EJ, Hansen BE, Schouten WR. Integrity of the anal sphincters after pouch-anal anastomosis: evaluation with three-dimensional endoanal ultrasonography. Dis Colon Rectum. 2005 Sep;48(9):1728-35. 65. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.
Bibliography 263 Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005 Nov;54(11):1604-9. Epub 2005 May 29. 66. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL; HBV 99-01 Study Group. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71. 67. Zonneveld, M. van, Honkoop, P., Hansen, B.E., Niesters, H.G.M., Darwish Murad, S., Man, R.A. de, Schalm, S.W. en Janssen, H.L.A. Gunstig langetermijneffect bij responders op interferonbehandeling onder patiënten met chronische hepatitis B in vergelijking tot non-responders; retrospectief onderzoek OOR- SPRONKELIJKE STUKKEN 2005; 149(27); 1510-5 68. Brakel, K., Overhagen, H. van, Heijenbrok, M.W., Kasteren, J.H.L.M. van, Moosdijk, C.N.F. van de, Roldaan, A.C. en Hansen, B.E. Opsporing en diagnostiek van supraclaviculaire lymfekliermetastasen bij patiënten met aanwijzingen voor longkanker door palpatie, echografi e en CT. OORSPRONKELIJKE STUKKEN 2005; 149(4); 189-95 69. Ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HL. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. Hepatology. 2006 Sep;44(3):721-7. 70. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol. 2006 Sep;41(9):1087-94. 71. Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. J Hepatol. 2006 Oct;45(4):539-46. Epub 2006 Jun 30. 72. Ter Borg PC, Schalm SW, Hansen BE, van Buuren HR; for the Dutch PBC study group. Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients. Am J Gastroenterol. 2006 Sep; 101(9):2044-50. 73. Leeuwenburgh I, Van Dekken H, Scholten P, Hansen BE, Haringsma J, Siersema PD, Kuipers EJ. Oesophagitis is common in patients with achalasia after pneumatic dilatation. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1197-203. 74. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006 Feb;101(2):297-303. 75. van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HL, Schalm SW, de Man RA.
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144:
Cha pter 3.2 Discriminant analysis
Page 145 and 146:
Introduction Discriminant analysis
Page 147 and 148:
Discriminant analysis using a MLMM
Page 149 and 150:
Estimation Discriminant analysis us
Page 151 and 152:
Page 153 and 154:
where wi,k(y i, θ) = (k =1,...,K).
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Appendix Discriminant analysis usin
Page 175:
Cha pter 4 Statistical models of ea
Page 178 and 179:
Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181:
Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183:
Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185:
Chapter 4.1 182 Figure 1.
Page 186 and 187:
Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189:
Chapter 4.1 186 suppression in seru
Page 190 and 191:
Chapter 4.1 188 13. Seifer M, Hamat
Page 193 and 194:
Cha pter 4.2 Viral dynamics during
Page 195 and 196:
INTRODUCTION Viral dynamics during
Page 197 and 198:
Viral dynamics during tenofovir the
Page 199 and 200:
Page 201 and 202:
log HBV DNA (copies/mL) 10.0 9.0 8.
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 211 and 212:
Chap ter 4.3 Modelling of early vir
Page 213 and 214: INTRODUCTION HBV viral kinetics dur
Page 215 and 216: HBV viral kinetics during PEG-IFN 2
Page 229: HBV viral kinetics during PEG-IFN 2
Page 233 and 234: SUMMARY AND CONCLUSION Summary and
Page 235 and 236: Summary and conclusion 233 The mode
Page 237 and 238: Summary and conclusion 235 The infe
Page 239: Summary and conclusion 237 Early st
Page 243 and 244: SAMENVATTING EN CONCLUSIE Samenvatt
Page 245 and 246: Samenvatting en conclusie 243 Er we
Page 247 and 248: Samenvatting en conclusie 245 Data
Page 249 and 250: Samenvatting en conclusie 247 Behan
Page 253: Dan kwoord
Page 256 and 257: Dankwoord 254 Lieve Marion en Margr
Page 259 and 260: BIBLI OGRAPHY Bibliography 257 1. K
Page 261 and 262: Bibliography 259 Interferon-ribavir
Page 263: Bibliography 261 Long term clinical
Page 267 and 268: Bibliography 265 Genetic characteri
Page 269: Bibliography 267 106. Reijnders JG,
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?